Abstract
Results from this study show 34.5% (403/1171) of Staphylococcus aureus from Latin America are resistant to three or more drug classes, while 21% (245/1171) are resistant to at least four drug classes. Tigecycline inhibited 100% of all multi-drug resistant (MDR) Staphylococcus aureus from Latin America at or below an MIC of 0.5 mcg/mL. The in vitro activity of tigecycline was equivalent to linezolid and vancomycin against all S. aureus. All of the multi-drug resistant S. aureus were resistant to oxacillin (methicillin-resistant phenotype). The in vitro activity of tigecycline in this study suggests that tigecycline should be seriously considered for the treatment of S. aureus that are resistant to multiple drugs and multiple drug classes including the methicillin-resistant phenotype. BACKGROUND
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
